TGFβ/Smad3 Signal Pathway Is Not Required for Epidermal Langerhans Cell Development  by Xu, Ying-Ping et al.
TGFb/Smad3 Signal Pathway Is Not Required for Epidermal
Langerhans Cell Development
Journal of Investigative Dermatology (2012) 132, 2106–2109; doi:10.1038/jid.2012.71; published online 22 March 2012
TO THE EDITOR
Epidermal Langerhans cells (LCs) are
professional antigen-presenting dendrit-
ic cells that reside in the epidermis and
form the first immunological barrier to
the external environment (Romani et al.,
2010). Although considerable progress
has been made in identifying the devel-
opmental requirement of LCs, the
mechanisms that regulate LC develop-
ment and homeostasis are still not fully
elucidated. Transforming growth factor-
b1 (TGF-b1) is one of the key regulators
to control LC development and homeo-
stasis. LCs are absent in mice that lack
TGF-b1, owing to a failure in LC differ-
entiation, survival, or both (Borkowski
et al., 1996; Kaplan et al., 2007; Zahner
et al., 2011). This finding is further
supported by the dependence of LCs
development on other TGFb1-related
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Figure 1. Smad3 is not required for ontogeny and homeostasis of epidermis LCs. (a, b) Epidermal suspensions prepared from the ears and trunk skin of Smad3
knockout (KO) and wild-type (WT) littermates on days 0, 1, 3, 8 after birth, as well as at 3 and 5 weeks old, were stained with anti-Langerin and
anti-MHCII Abs and analyzed by flow cytometry. At each time point, 3–5 mice were analyzed, P40.05; (c) Epidermal sheets from Smad3 KO and WT littermates
at 0 days post-birth were stained with anti-MHCII. (d) Epidermal sheets from Smad3 KO and WT littermates at 5 weeks old were stained with anti-MHC II
(red) and Langerin (green). One representative epidermal sheet is shown from n¼ 3 mice analyzed. Bar¼ 10 mm, original magnification  200. LC, Langerhans
cell; MHCII, major histocompatibility complex II.
Abbreviations: KO, knockout; LC, Langerhans cell; TGF-b1, transforming growth factor-b1; WT, wild type
2106 Journal of Investigative Dermatology (2012), Volume 132
Y-P Xu et al.
TGFb/Smad3 Signal Pathway Is Not Needed for LC Development
molecules, including inhibitor of DNA
binding 2, a TGFb1-induced inhibitor
of helix–loop–helix transcription factors
(Hacker et al., 2003), and Runx3,
specifically expressed by mature DCs
and mediates their response to TGFb1
(Fainaru et al., 2004). Furthermore,
TGF-b1 is also required to maintain
the pool of immature LCs in the
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Figure 2. Smad3 is not an essential factor to control epidermis Langerhans cell (LC) maturation and LC uptaking-antigen ability. (a, b) Epidermal suspensions
freshly isolated from the ears and trunk skin of Smad3 knockout (KO) and wild-type (WT) littermates at 5 weeks old were stained with anti-Langerin, MHCII,
CD80, and CD86 Abs and analyzed by flow cytometry. No significant differences were observed in the ratios (a) as well as in the expression (b; average mean
fluorescence intensity (MFI)±SD). Three to five mice were analyzed, P40.05. (c, d) Epidermal suspensions isolated from the ears and trunk skin of Smad3 KO
and WT littermates at 5 weeks old were cultured in RPMI for 60 hours, then stained with anti-Langerin, MHCII, CD80, and CD86 Abs and analyzed
by flow cytometry. No significant differences were observed in the ratios (c) as well as in the expression (d). Three to five mice were analyzed, P40.05.
(e, f) Phagocytic ability of LCs (CD45.2 and MHCII-double positive cells) was assessed by flow cytometry of FITC-Dextran phagocytosis. LCs from Smad3
KO mice were able to phagocyte FITC-Dextran as efficiently as LCs from WT control (e). Numbers in histogram indicate geometric mean fluorescence of test
samples (f). Ctrl, control (cells incubated with FITC-Dextran at 4 1C). Data represent one of at least three experiments with similar results. (g) The model of
induction of signaling responses by transforming growth factor (TGF)-b1 in skin LCs. MHCII, major histocompatibility complex II.
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epidermis (Kel et al., 2010). Although
TGF-b1 is expressed by both keratino-
cytes and LCs, an autocrine source of
TGF-b1 from LCs is required for LC
development (Kaplan et al., 2007).
Taken together, TGF-b1 is essential for
the ontogeny, homeostasis, and func-
tion of epidermal LCs. However, the
intracellular signaling pathway of TGF-
b1 in epidermal LCs remains elusive.
In a well-defined classical TGF-b
linear signaling pathway, once activated,
TGF-b1 signals through its two cell surface
receptors, TGF-b receptor 1 (TbR1) and
TGF-b receptor 2 (TbR2), leading to
Smad-mediated transcriptional regula-
tion. There are eight Smads: Smad1 to
Smad8. Smad2 and Smad3 are activated
through carboxy-terminal phosphoryla-
tion by TGFb1. These receptor-activated
Smads (R-Smads) are released from the
receptor complex to form a heterotri-
meric complex with a common Smad4,
and translocate into the nucleus to
regulate the transcription of target
genes (Tsukazaki et al., 1998; Derynck
and Zhang, 2003). In addition, TGF-b1
also can activate other signaling cas-
cades, including mitogen-activated pro-
tein kinase pathways (Itoh et al., 2000;
Massague, 2000; Moustakas et al.,
2001). Unlike mice with the conven-
tional disruptions of Smad2 and Smad4
that are lethal, mice with Smad3
deficiency are viable and can survive.
However, Smad3 knockout (KO) mice
develop progressive diseases, including
leukocytosis and massive inflammation.
The loss of Smad3 results in multiple
cell defects, including T cells, neutriphils,
and macrophage (Yang et al., 1999;
Werner et al., 2000). Here we used
Smad3 KO mice (Datto et al., 1999) to
directly test if TGFb/Smad3 signaling
pathway is involved in the ontogeny
and homeostasis of epidermal LCs.
During LC early development, a single
wave of LC precursors recruited in the
epidermis around embryonic day 18,
which subsequently differentiate into
LCs after birth, and LCs then undergo a
massive burst proliferation during the
first week of life to form a typical LC
network (Chorro et al., 2009). Given
that TGF-b signals are required for onto-
geny and maintaining of LCs in the
epidermis, we first assessed if Smad3
is required for LC homeostasis in vivo.
Epidermal cell suspensions prepared
from the ears and dorsal skin of Smad3
KO mice and wild-type (WT) litter-
mates, on day 0, 1, 3, 8 after birth, as
well as at 3- and 5-week old, were
stained with anti-Langerin and anti-
MHCII Abs. As shown in Figure 1a
and b, we did observe a 3- to 4-fold
expansion of LCs from 0.78±0.11% on
day 0 to 2.72±0.14% on day 3 in WT
mice. Langerin expression was unde-
tectable in MHCIIþ LCs in the epidermis
on day 0 and 1, but upregulated Langerin
expression was detected in about
70–80% LCs by day 3, which is con-
sistent with recent report (Chorro et al.,
2009; Kel et al., 2010). However, there
were no significant differences on the
ratios of epidermal LCs between Smad3
KO and WT mice at any time points by
flow cytometry (Figure 1a and b) and
immunohistological staining at day 0
after born and 5 weeks old (Figure 1c
and d). Thus, Smad3 is not required in
the TGF-b signal pathway for oncogeny
and homeostasis of epidermis LCs.
Upon activation by various stimuli,
immature LCs residing in epidermis
collect antigen and increase their major
histocompatibility complex II (MHCII)
and costimulatory molecules, including
CD80 and CD86, and then migrate to
T-cell areas of draining lymph nodes,
leading to immune responses (Romani
et al., 2010). However, loss of TbR1 in
LCs makes LC spontaneous maturation,
suggesting the TGF-b signal as an
essential pathway to control the im-
mature state of LCs (Kel et al., 2010).
We next tested if TGF-b/Smad3 signal-
ing pathway is required for maintaining
the immature state of epidermal LCs. As
shown in Figure 2a, the frequencies of
CD80þ LCs and CD86þ LCs were
comparable between Smad3 KO and
WT mice. Furthermore, the expression
levels of MHCII, CD80, and CD86 on
LCs, represented by mean fluorescence
intensity, were not changed (Figure 2b).
LC maturation in Smad3 KO mice were
further evaluated after in vitro epider-
mal culture. As shown in Figure 2c,
after 60 hours culture, both the per-
centages of CD86- and CD80-positive
LCs and MHCIIhigh LCs as well as
the relative CD80, CD86, and MHCII
expression levels on LCs (Figure 2d)
were significantly increased in Smad3
KO and WT mice compared with
unstimulation condition (Figure 2a and
b), but there was no significant difference
between Smad3 KO and WT mice
(P40.05). Thus, the lack of Smad3
signaling does not affect the immature
state of LCs as well as LC maturation.
Owing to their physical location,
LCs acquire and process antigens. To
evaluate the role of Smad3 in antigen
phagocytic function of LCs, freshly
isolated epidermal cells from KO and
WT mice were incubated at 37 or 4 1C
(as control) with FITC-Dextran for
45 minutes and then stained with anti-
mouse MHCII and CD45.2 Abs. As
shown in Figure 2e, the phagocytic
capacity of LCs in Smad3 KO mice
had no significant difference (P40.05)
compared with the WT LCs, based on
the ratio of FITC-positive LCs (Figure
2e) or mean fluorescence intensity
expression levels (Figure 2f). Thus, lack
of Smad3 signal pathway does not
affect LC phagocytosis.
In summary, lack of Smad3 surpris-
ingly does not significantly interrupt the
development and immature state of
epidermal LCs, and Smad3-deficient
LCs have normal maturation and pha-
gocytosis. Our data indicate that Smad3
is not required in the TGF-b signal path-
way for ontogeny, homeostasis, and func-
tion of epidermal LCs. Recent report
indicated that Smad2 and Smad3 were
redundantly essential for TGF-b–mediated
induction of Foxp3-expressing regulatory
T cells and suppression of IFN-g produc-
tion in CD4þ T cells (Takimoto et al.,
2010). This raises the possibility that
Smad2/Smad3 redundancy may also ex-
ist in TGF-b/Smads pathways in LCs. In
addition, non-TGF-b/Smads pathways
may also regulate LC ontogeny and
homeostasis (Figure 2g). Further investi-
gations are warranted to clarify the TGF-b
signaling pathways through which TGF-b
controls LC ontogeny and homeostasis.
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TO THE EDITOR
Itch is a common symptom in various
forms of dermatitis characterized by
dry skin, such as senile xerosis and
atopic dermatitis (AD). It is defined as
an unpleasant sensation that provokes
a desire to scratch and, because itch-
elicited scratching aggravates lesions of
the skin, the itch is intensified (Ikoma
et al., 2006). Therefore, reduction of
itching and scratching is an effective
strategy for preventing aggravation
of skin lesions and improving quality
of life. Histamine is the best-known
pruritogen and has been regarded as a
main target for antipruritic therapies,
but H1 receptor (histamine H1R) an-
tagonists are often ineffective against
certain kinds of pruritus including dry
skin pruritus (Wahlgren et al., 1990).
It is suggested that mediators other than
histamine also have a key role in itch;
for example, physiological temperature,
inflammatory mediators, and nitric
oxide. These putative pruritogens are
also recognized as activators of transi-
ent receptor potential (TRP) V3 (Xu
et al., 2002; Hu et al., 2006; Yoshida
et al., 2006), which is a warm-sensitive
Ca2þ -permeable cation channel highly
expressed in epidermal keratinocytes
(Peier et al., 2002). Interestingly, we
indicated previously that a gain-
of-function mutation in TRPV3 caused
itchy dermatitis in rodents (Asakawa
et al., 2006; Yoshioka et al., 2009).
However, we could not sufficiently
suggest a possibility of TRPV3 as a
therapeutic target of pruritus. Hence,
we focused on TRPV3 as a new
therapeutic target for histamine H1R
antagonist–resistant pruritus and carried
out experiments using ICRTRPV3/
mice to determine the maximum thera-
peutic impact of TRPV3 for a certain
type of itch (Inagaki et al., 2001).
The distinguishing feature of
ICRTRPV3/ mice is the presence of
wavy whiskers. Information regarding
TRPV3-knockout mice is shown in
Supplementary Figure S1 online. In
contradiction to previous reports (Moqrich
et al., 2005; Cheng et al., 2010), we did
not find that mice lacking the TRPV3 gene
also exhibit wavy hair coat (data not
shown). This discrepancy may be due,
partially, to the differences in mice
strains used in the different studies.
Recently, Miyamoto et al. (2002)
developed a murine model of dry skin
Abbreviations: AD, atopic dermatitis; AEW, acetone ether water; PGP9.5, protein gene product 9.5;
TRPV3, transient receptor potential vanilloid subfamily 3
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